60 news items
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
BMY
22 May 24
a candidate drug in 2025.
NeoPhore is focused on building a pipeline of small molecule drugs targeting novel
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
ABBV
BMY
17 May 24
, with a price target of $200.
Cantor expects that Bristol-Myers
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
BMY
16 May 24
Myers Squibb scientists designed Sotyktu to selectively target TYK2, thereby inhibiting signaling
Editas Medicine Announced A Two-year Extension To The Alpha-Beta T Cell Collaboration With Bristol Myers Squibb; The Extension Also Has Options To Extend The Collaboration For Up To An Additional Two Years
BMY
EDIT
1 May 24
Under the collaboration, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs are currently
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
BMY
29 Apr 24
leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted immune medicines with Bristol Myers Squibb's world
hdlhkqwn8wpmxq5nsj9h03cpmrep29u08azzbuz5wn6w
BMY
EDU
LKQ
28 Apr 24
cut the price target.
Southwest Airlines Company
bbis0
BMY
26 Apr 24
0
Analysts have recently evaluated Bristol-Myers Squibb and provided 12-month price targets. The average
bhpgw8jzhrqv26hnhtf0e5dlbuej9hm8x0n9
ADMA
ANIP
BMY
25 Apr 24
States for the treatment of schizophrenia in adults, with a target action date of Sep 26, 2024.
BMY also acquired clinical-stage
22st0wu uivbp
ACON
AIRE
ATNI
25 Apr 24
% to $2.2250 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced an $8 price target.
Aclarion
vg9em67h48hyeh9d6pon26svoobm
BMY
25 Apr 24
programs currently targeting solid tumors.
Through
wahv2x7q7kp6wt6wfrvg5ao
BMY
19 Apr 24
been targeting a price range from $43.0 to $55.0 for Bristol-Myers Squibb over the last 3 months.
Analyzing Volume & Open Interest